Lung Cancer Clinical Trials

Showing 1621-1640 of 2,032 trials

Registry Study on Biological Disease Profile and Clinical Outcome in Patients With Newly Diagnosed or Existent Lung Cancer The LuCa Biology and Outcome (BiO)-Project

NCT02613637

Registry Study on Biological Disease Profile and Clinical Outcome in Patients with Newly Diagnosed or Existent Lung Cancer The LuCa Biology and Outcome (BiO)-Project

Lung Cancer

University of Ulm2,000 participantsStarted May 2014

Esslingen am Neckar, Germany • Stuttgart, Germany • Ulm, Germany

COMPLETEDNA

Mutation Detection of EBUS-TBNA Specimens Using NGS

NCT02420405

The objective of the study was to compare the value of routine gene testing and next-generation sequencing (NGS) in detecting gene mutations of small specimens obtained by endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) and get the knowledge of how many EBUS-TBNA samples were adequate for NGS.

Lung Cancer

Jiayuan Sun78 participantsStarted Mar 2015

Shanghai, Shanghai Municipality, China

COMPLETEDPhase 3

Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery

NCT00003901

RATIONALE: Prognostic testing for early signs of metastases may help doctors detect metastases early and plan more effective treatment. PURPOSE: Phase III trial to study the relationship between early signs of metastases and survival in patients who have stage I, stage II, or stage III non-small cell lung cancer that can be removed by surgery.

Lung Cancer

Alliance for Clinical Trials in Oncology1,310 participantsStarted Jul 1999

Mobile, Alabama, United States • Mobile, Alabama, United States • Los Angeles, California, United States +55 more locations

Registry Study on Biological Disease Profile and Clinical Outcome in Patients With Newly Diagnosed or Existent Lung Cancer The LuCa Biology and Outcome (BiO)-Project

Mutation Detection of EBUS-TBNA Specimens Using NGS

Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery

Related Searches

Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients

Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma

Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients

EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer

Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer

Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer

Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer

SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations

Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer

Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy

An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer